Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Resch, B; Sommer, C; Nuijten, MJ; Seidinger, S; Walter, E; Schoellbauer, V; Mueller, WD.
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
PEDIATR INFECT DIS J. 2012; 31(1): e1-e8.
Doi: 10.1097/INF.0b013e318235455b
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Resch Bernhard
- Co-Autor*innen der Med Uni Graz
- Müller Wilhelm
- Sommer Constanze
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: To assess the cost-effectiveness of palivizumab, a monoclonal antibody against respiratory syncytial virus (RSV), in infants at high risk for severe RSV lower respiratory tract infection, such as premature infants, infants with bronchopulmonary dysplasia, and those with congenital heart disease, based on long-term epidemiologic data from Austria. METHODS: A decision-tree model was used, and the analysis was based on a lifetime follow-up investigating cost-effectiveness of palivizumab versus no RSV infection prevention. The primary perspective of the study was that of the healthcare system, the second that of society. Cost and effects were discounted by 5%. The base case analysis included only direct medical costs, and a scenario analysis included various indirect costs. RESULTS: Analyses were based on epidemiologic data on a total of 1579 children hospitalized because of RSV lower respiratory tract infection during 16 seasons. The incremental cost-effectiveness ratio for the first outcome measure (life years gained) amounted to discounted costs of Euro34,956 (for all preterm infants), Euro35,056 (for < 33 weeks' gestational age [wGA] infants), Euro35,233 (for 33-35 wGA infants), Euro35,611 (for infants with bronchopulmonary dysplasia), and Euro8956 (for infants with congenital heart disease). Use of palivizumab compared with no prophylaxis had an incremental cost-utility ratio of Euro26,212, Euro26,292, Euro24,392, Euro24,654, and Euro8484, respectively, per quality-adjusted life years. Results from the society perspective were more cost-effective in all study populations. An additional scenario analysis with 7 injections for the 33 to 35 wGA group revealed cost-effectiveness as well. CONCLUSIONS: Our results based on nationwide long-term epidemiologic data suggest that palivizumab is cost-effective in prevention of RSV disease in high-risk infants.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - economics
- Antibodies, Monoclonal, Humanized - economics
- Antibodies, Monoclonal, Humanized - epidemiology
- Chemoprevention -
- Cost-Benefit Analysis -
- Decision Trees -
- Female -
- Hospitalization -
- Humans -
- Infant -
- Infant, Newborn -
- Infant, Premature -
- Infant, Premature, Diseases - epidemiology
- Male -
- Respiratory Syncytial Virus Infections - epidemiology
- Respiratory Syncytial Viruses - drug effects
- Respiratory Tract Infections - epidemiology
- Risk -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- cost-effectiveness
- epidemiology
- palivizumab
- premature infant
- respiratory syncytial virus